O
CRSP icon

OrbiMed’s CRISPR Therapeutics CRSP Stock Holding History

OrbiMed’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-612,700
Closed -$68.6M – 160
2021
Q3 		$68.6M Buy
612,700
+93,700
+18% +$11.8M 0.75% 42
2021
Q2 		$84M Sell
519,000
-33,500
-6% -$4.07M 0.85% 39
2021
Q1 		$67.3M Buy
552,500
+100,700
+22% +$15.2M 0.63% 47
2020
Q4 		$69.2M Sell
451,800
-178,204
-28% -$21.1M 0.61% 46
2020
Q3 		$52.7M Sell
630,004
-67,520
-10% -$5.99M 0.66% 45
2020
Q2 		$51.3M Buy
697,524
+146,324
+27% +$8.56M 0.72% 45
2020
Q1 		$23.4M Sell
551,200
-215,178
-28% -$11.1M 0.39% 60
2019
Q4 		$46.7M Buy
766,378
+249,978
+48% +$13.6M 0.67% 47
2019
Q3 		$21.2M Buy
+516,400
New +$24.7M 0.4% 60
2018
Q4 		– Sell
-496,200
Closed -$22M – 136
2018
Q3 		$22M Hold
496,200
– – 0.27% 82
2018
Q2 		$29.2M Buy
496,200
+391,799
+375% +$22.3M 0.35% 69
2018
Q1 		$4.77M Buy
+104,401
New +$4.31M 0.06% 119
2017
Q4 		– Sell
-372,191
Closed -$6.65M – 135
2017
Q3 		$6.65M Hold
372,191
– – 0.06% 117
2017
Q2 		$5.96M Hold
372,191
– – 0.06% 110
2017
Q1 		$8.1M Hold
372,191
– – 0.09% 103
2016
Q4 		$7.54M Buy
+372,191
New +$6.96M 0.1% 100

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

OrbiMed's CRSP Position: Q4 2021 in Review

OrbiMed sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 612,700 shares — an estimated $68.6M sold.

OrbiMed first reported a position in CRSP in Q4 2016 and held it in 16 quarters. The position peaked at $84M in Q2 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • OrbiMed reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • OrbiMed sold 612,700 CRISPR Therapeutics shares in Q4 2021, an estimated $68.6M.
  • OrbiMed first reported a position in CRISPR Therapeutics in Q4 2016 and held it in 16 quarters.
  • OrbiMed's CRISPR Therapeutics position peaked at $84M in Q2 2021.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.